ABT-670

ABT-670
Identifiers
	IUPAC name 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide;
CAS Number	630119-43-6 ;
PubChem CID	16094676;
ChemSpider	17252978 ;
UNII	4L6071XH2J;
ChEMBL	ChEMBL219182 ;
CompTox Dashboard (EPA)	DTXSID30212235 ;
Chemical and physical data
Formula	C19H23N3O2
Molar mass	325.404 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-][n+]1ccccc1C(CC3)CCN3CNC(=O)c(c2)cccc2C;
	InChI InChI=1S/C19H23N3O2/c1-15-5-4-6-17(13-15)19(23)20-14-21-11-8-16(9-12-21)18-7-2-3-10-22(18)24/h2-7,10,13,16H,8-9,11-12,14H2,1H3,(H,20,23) ; Key:PUMMPCXNEPHBNN-UHFFFAOYSA-N ;
(what is this?) (verify)

ABT-670 is a drug which acts as a potent, orally bioavailable dopamine agonist selective for the D₄ subtype, which was developed as a possible treatment for erectile dysfunction,[1] although its current uses are limited to scientific research.[2]

References

Patel, M. V.; Kolasa, T.; Mortell, K.; Matulenko, M. A.; Hakeem, A. A.; Rohde, J. J.; Nelson, S. L.; Cowart, M. D.; Nakane, M.; Miller, L. N.; Uchic, M. E.; Terranova, M. A.; El-Kouhen, O. F.; Donnelly-Roberts, D. L.; Namovic, M. T.; Hollingsworth, P. R.; Chang, R.; Martino, B. R.; Wetter, J. M.; Marsh, K. C.; Martin, R.; Darbyshire, J. F.; Gintant, G.; Hsieh, G. C.; Moreland, R. B.; Sullivan, J. P.; Brioni, J. D.; Stewart, A. O. (2006). "Discovery of 3-Methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-\2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an Orally Bioavailable Dopamine D4Agonist for the Treatment of Erectile Dysfunction". Journal of Medicinal Chemistry. 49 (25): 7450–7465. doi:10.1021/jm060662k. PMID 17149874.
Richards N, Wayman C, Allers KA. Electrophysiological actions of the dopamine agonist apomorphine in the paraventricular nucleus during penile erection. Neuroscience Letters. 3 September 2009 doi:10.1016/j.neulet.2009.08.078

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Patel, M. V.; Kolasa, T.; Mortell, K.; Matulenko, M. A.; Hakeem, A. A.; Rohde, J. J.; Nelson, S. L.; Cowart, M. D.; Nakane, M.; Miller, L. N.; Uchic, M. E.; Terranova, M. A.; El-Kouhen, O. F.; Donnelly-Roberts, D. L.; Namovic, M. T.; Hollingsworth, P. R.; Chang, R.; Martino, B. R.; Wetter, J. M.; Marsh, K. C.; Martin, R.; Darbyshire, J. F.; Gintant, G.; Hsieh, G. C.; Moreland, R. B.; Sullivan, J. P.; Brioni, J. D.; Stewart, A. O. (2006). "Discovery of 3-Methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-\2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an Orally Bioavailable Dopamine D4Agonist for the Treatment of Erectile Dysfunction". Journal of Medicinal Chemistry. 49 (25): 7450–7465. doi:10.1021/jm060662k. PMID 17149874.

[2] Richards N, Wayman C, Allers KA. Electrophysiological actions of the dopamine agonist apomorphine in the paraventricular nucleus during penile erection. Neuroscience Letters. 3 September 2009 doi:10.1016/j.neulet.2009.08.078

ABT-670

See also

References